Johnson & Johnson (NYSE:JNJ) is Hutner Capital Management Inc.'s 10th Largest Position

Hutner Capital Management Inc. raised its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 6.2% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 46,286 shares of the company's stock after buying an additional 2,700 shares during the quarter. Johnson & Johnson makes up about 3.2% of Hutner Capital Management Inc.'s investment portfolio, making the stock its 10th largest holding. Hutner Capital Management Inc.'s holdings in Johnson & Johnson were worth $6,694,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. South Plains Financial Inc. acquired a new position in Johnson & Johnson in the 4th quarter valued at approximately $1,456,000. Blue Rock Wealth Management LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $221,000. Cypress Advisory Group LLC bought a new position in Johnson & Johnson in the 4th quarter worth approximately $818,000. FAS Wealth Partners Inc. raised its holdings in Johnson & Johnson by 1.7% during the 4th quarter. FAS Wealth Partners Inc. now owns 38,738 shares of the company's stock worth $5,602,000 after purchasing an additional 664 shares during the last quarter. Finally, Eagle Strategies LLC lifted its holdings in Johnson & Johnson by 5.3% in the fourth quarter. Eagle Strategies LLC now owns 3,923 shares of the company's stock valued at $567,000 after buying an additional 196 shares during the period. Institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

A number of research firms recently issued reports on JNJ. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their price target for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Stifel Nicolaus dropped their price objective on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a research note on Thursday, January 23rd. Barclays reduced their target price on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Finally, Benchmark raised Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $171.82.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Price Performance

Shares of NYSE JNJ traded up $1.63 during midday trading on Friday, hitting $156.09. 5,973,317 shares of the company's stock were exchanged, compared to its average volume of 7,885,287. The business's fifty day moving average price is $158.85 and its two-hundred day moving average price is $154.61. The company has a market cap of $375.56 billion, a price-to-earnings ratio of 23.47, a PEG ratio of 2.56 and a beta of 0.49. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.33%. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is currently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.